Analysed IONIS PHARMACEUTICALS INC (IONS:NASDAQ) News Sources
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
03-08-2026
fool.com
RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors
17-08-2026
yahoo.com
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
20-08-2026
yahoo.com
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...
29-07-2026
yahoo.com
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?
15-08-2026
yahoo.com
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
28-08-2026
biopharmadive.com
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
28-08-2026
stocktwits.com
What is the current price of IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The current price of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is $61.05.
IONIS PHARMACEUTICALS INC (IONS:NASDAQ) absolute price change since previous trading day?
The absolute price change of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) since the previous trading day is $-1.38.
IONIS PHARMACEUTICALS INC (IONS:NASDAQ) percentage price change since previous trading day?
The percentage price change of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) since the previous trading day is -2.2105%.
What is the most recent average sentiment score for IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The most recent average sentiment score for IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The most recent sentiment for IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is .
SEC-8K** Filing Available For IONIS PHARMACEUTICALS INC (IONS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.